Associations Between Paternally Transmitted Fetal IGF2 Variants and Maternal Circulating Glucose Concentrations in Pregnancy

TABLE 4

IGF-II protein contents and IGF2 transcript expression (expressed relative to a composite expression score of TOP1, UBC, and YWHAZ) in term placentas from the Cambridge Baby Growth Study having genotypes associated with either higher or lower maternal glucose concentrations at week 28 of the pregnancy

Placentas with IGF2 genotypes associated with higher maternal glucose concentrations Placentas with IGF2 genotypes associated with lower maternal glucose concentrations P value
IGF-II protein (% of total protein) 0.93 (0.70–1.44) (n = 21) 0.67 (0.58–0.99) (n = 29) 0.028
IGF2 transcript variant 1 expression 0.143 (0.098–0.190) (n = 16) 0.091 (0.074–0.174) (n = 19) 0.2
IGF2 transcript variant 2 expression 0.101 (0.072–0.149) (n = 16) 0.074 (0.053–0.131) (n = 19) 0.3
IGF2 transcript variant 3 expression 0.040 (0.023–0.069) (n = 16) 0.074 (0.043–0.117) (n = 19) 0.018
Antisense IGF2 expression 0.065 (0.040–0.103) (n = 16) 0.065 (0.053–0.092) (n = 19) 0.7
  • The INS-IGF2 readthrough transcripts were undetectable throughout. Data are median (interquartile range) analyzed using Mann-Whitney U tests.

This Article

  1. Diabetes vol. 60 no. 11 3090-3096